Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR6 | P46095 | 20/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20524623 | 0.86 | GPR6 (0.74) | GPR6 | |
| SCHEMBL30323186 | 0.86 | GPR6 (0.74) | GPR6 | |
| SCHEMBL22712163 | 0.84 | GPR6 (1.00) | GPR6 | |
| SCHEMBL22712000 | 0.84 | GPR6 (1.00) | GPR6 | |
| SCHEMBL22711979 | 0.83 | GPR6 (1.00) | GPR6 | |
| SCHEMBL26143929 | 0.83 | GPR6 (0.70) | GPR6 | |
| SCHEMBL22712157 | 0.82 | GPR6 (1.00) | GPR6 | |
| SCHEMBL26144272 | 0.82 | GPR6 (0.67) | GPR6 | |
| SCHEMBL29002498 | 0.82 | GPR6 (0.69) | GPR6 | |
| SCHEMBL22712222 | 0.82 | GPR6 (1.00) | GPR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3600312-B1 | PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6 | TAKEDA PHARMACEUTICALS CO (JP) | 2023-05-17 | — | — | EP | disclosed |
| CN-110520127-B | Piperidinyl-substituted and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6 | 武田药品工业株式会社 | 2023-05-16 | — | — | CN | disclosed |
| US-11426397-B2 | Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-08-30 | — | — | US | disclosed |
| US-20200375969-A1 | PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6 | TAKEDA CALIFORNIA, INC. | 2020-12-03 | — | — | US | disclosed |
| US-20200375969-A1 | PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6 | TAKEDA CALIFORNIA, INC. | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11426397-B2 | Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6 | GPR6, GPR3, GPR68 | GPR6 1/4885 |
| US-20200375969-A1 | PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6 | GPR6, GPR3, GPR68 | GPR6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.